Vabysmo:
US: ~30% naive patients, ~70% switches (mostly from aflibercept)；
US market share reaches 15% in nAMD and 9% in DME；
| 发布于: | 雪球 | 转发：1 | 回复：3 | 喜欢：0 |
Vabysmo:
US: ~30% naive patients, ~70% switches (mostly from aflibercept)；
US market share reaches 15% in nAMD and 9% in DME；
长效eylea延期巨伤